论文部分内容阅读
目的:研究阿利克仑,一种直接的肾素抑制剂,对1型糖尿病大鼠模型氧化应激的影响。方法:SD大鼠随机分为4组(9只/组):对照组(CON),阿利克仑[30 mg/(kg.day)]处理对照组(C+A),糖尿病组(DM),阿利克仑[30 mg/(kg.day)]处理糖尿病组(D+M)。每天灌胃给药5周后,比较各组间改善效果。结果:与CON组比较,DM组血清中黄嘌呤氧化酶(XOD)活力增强(P<0.01),血清一氧化氮(NO)浓度升高(P<0.01),主动脉上活性氧增多;与DM组比较,阿利克仑处理(D+A)正常化这些数据(P<0.05)。阿利克仑处理不改变DM组减轻的体重(P<0.01)、增高的血糖和糖化血红蛋白水平(P<0.001)。结论:阿利克仑这种新型的直接肾素抑制剂可提高1型糖尿病大鼠抗氧化能力,抑制氧化应激。
AIM: To investigate the effect of aliskiren, a direct renin inhibitor, on oxidative stress in type 1 diabetic rats. Methods: The SD rats were randomly divided into 4 groups (9 rats / group): control group (CON), aliskiren (30 mg / (kg.day) Diabetic group (D + M) was treated with aliskiren [30 mg / (kg.day)]. After 5 days of oral administration, the improvement effect was compared among the groups. Results: Compared with CON group, the activity of xanthine oxidase (XOD) in serum of DM group increased (P <0.01) and the concentration of serum nitric oxide (NO) increased (P <0.01) In the DM group, Aliskiren (D + A) normalized these data (P <0.05). Aliskiren did not change weight-loss (P <0.01), increased blood glucose and HbA1c (P <0.001) in DM group. Conclusion: Aliskiren, a new direct renin inhibitor, can improve the antioxidant capacity and inhibit oxidative stress in type 1 diabetic rats.